Upstream Bio, Inc. UPB
Upstream Bio, Inc. (Nasdaq: UPB) is a respiratory drug developer. Its lead program, verekitug, is in Phase 2 for Severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and COPD (anti-TSLP receptor antibody). Its next catalyst on record is verekitug - severe asthma and CRSwNP: Initiate dosing in Phase 3 trials (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: verekitug - severe asthma and CRSwNP — Initiate dosing in Phase 3 trials (Q1 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| verekitug - severe asthma | Severe asthma (Phase 2 positive topline Feb 2026; Phase 2 LTE ongoing; Phase 3 planned) | antibody | Phase 2 |
| verekitug - CRSwNP | Chronic rhinosinusitis with nasal polyps (Phase 2 positive topline Sept 2025; Phase 3 planned) | antibody | Phase 2 |
| verekitug - COPD | COPD (Phase 2 enrollment complete) | antibody | Phase 2 |
Recent results and decisions
- Feb 11, 2026met Phase 2 VALIANT met primary endpoint: AAER reduction 56% (p<0.0003) at 100 mg q12w and 39% (p<0.02) at 400 mg q24w vs placebo.
VALIANT met the study’s primary endpoint of a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation rate (AAER) with both every 12 week (q12w) and every 24 week (q24w) dosing
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.